ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company,...
Year: 2022
Philips expands rollout of its ClarifEye augmented reality surgical navigation solution to Japan
Philips’ augmented reality (AR) surgical navigation solution ClarifEye Philips ClarifEye live AR guidance Philips ClarifEye AR guidance Philips Azurion October...
Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022
First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or...
IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana
New contract to provide broader access to diagnostics in emerging markets Louvain-La-Neuve, Belgium, October 13, 2022 – IBA (Ion Beam Applications S.A.,...
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022...
Fagron delivers topline growth of 21.5% to €173 million
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 October 2022 – 7.00 AM CET Fagron delivers topline growth of 21.5% to €173...
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia
PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative...
DICE Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its...
Castellum, Inc. Announces Pricing of $3,000,000 Public Offering and NYSE Listing
POTOMAC, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE: CTM) (“Castellum”, or the “Company”), a cybersecurity, electronic warfare,...
BioSyent Initiates First Dividend
MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce...
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
• No safety concerns noted in ongoing clinical trial• Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE...
Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022
TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services...
Loos, France, Isovital Headquarter, Oct 12th 2022 – Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDER
Loos, France, Isovital Headquarter, Oct 12th 2022 - Radiopharma Logistics Group (RLG); ISOTOPES SERVICES INTERNATIONAL (ISI). NEW SHAREHOLDERClaude Poliart, founder and manager...
Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
Novel name reflects expansion of capabilities and solutionsSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY),...
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on...
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Sientra Announces Preliminary Unaudited Third Quarter Financial Results and Signing of Senior Secured Loan Facilities With Deerfield Management
Anticipates total third quarter net sales of $21.5-$22.5 million, up 10-15% compared to the prior year period Restructured balance sheet...
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients...
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of...